New York lawmakers plan to hold a public hearing on September 30 to examine the medicinal value and risks of psilocybin, the psychoactive compound found in “magic mushrooms.” The Assembly Health Committee, led by Chairwoman Amy Paulin (D), announced the meeting as the state considers regulated pathways for supervised use.
The move comes as the FDA has designated psilocybin as a “breakthrough therapy” for major depression, suggesting it could outperform current treatments. Similar reforms have already passed in states like Colorado and Oregon.
Several bills have been introduced in New York to legalize or regulate psilocybin, but none have advanced out of committee. Lawmakers say the issue is pressing amid the state’s ongoing mental health crisis.
Read the full report at Marijuana Moment.